Drug Trial Radar · NCT00720811
Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs
Last checked: Nov 19, 2026Latest source record: Mar 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,456
Actual
Start
Oct 2009
Primary completion
Jan 2012
Study completion Jan 2012
Sponsor
- Lead sponsor
- Mbarara University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Makerere University; Ministry of Health, Uganda; Navrongo Health Research Centre, Ghana; National Malaria Research and Training Centre, Burkina Faso
- First posted
- Jul 23, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 months, up to 59 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to assess the value of incorporating a malaria RDT based strategy in HMM. The primary activity of the study wil be a two armed cluster randomised trial in two study sites in Uganda, one in Ghana and one in Burkina Faso. One of the Uganda sites is highly endemic and the other meso-endemic for malaria. In one arm the children will be treated presumptively for malaria with ACT (control arm) and the other arm the children will receive ACT only when they have a positive RDT result (implementation arm). The children in the implementation arm will also receive antibiotics if they have a raised respiratory rate. The primary outcome will be the recovery rate in the intervention arm compared to that of the control arm on Day 3. In addition, an acceptability assessment of RDTs in the community will be undertaken both before and after the intervention trial and a cost-effectiveness analysis of the RDT strategy will also be completed. For a sub-sample, microscopy slides will also be taken on Day 0 to demonstrate comparable levels of endemicity in control and intervention groups. These activities will be carried out over a two year period.
Conditions
- Malaria
- Pneumonia
Interventions
Artemether-lumefantrine combinationDrug
20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
amoxycillinDrug
amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
paracetamolDrug
paracetamol 500mg tablet \<36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
malaria rapid diagnostic test, respiratory rate timerDevice
malaria dipstick, and breath timer
Artemether-lumefantrine combinationDrug
20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recovery rate from fever at Day 3Time frame: Day 3
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
Sapone Site
Saponé, Burkina Faso
Kassena Nankana Site
Kassane, Ghana
Iganga Site
Iganga, Uganda
Mbarara Site
Mbarara, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.